Publications by authors named "Lesley Shane"

Claim this Profile
G
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States.
Kyle Paret, Hadi Beyhaghi, William L Herring, Josephine Mauskopf, Lesley G Shane

Vaccines (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
George Dranitsaris, Lesley G Shane, Seth Woodruff

J Oncol Pharm Pract· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.
Steven Simoens, Ira Jacobs, Robert Popovian, Leah Isakov, Lesley G Shane

Pharmacoeconomics· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug tendering: drug supply and shortage implications for the uptake of biosimilars.
George Dranitsaris, Ira Jacobs, Carol Kirchhoff, Robert Popovian, Lesley G Shane

Clinicoecon Outcomes Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars: Practical Considerations for Pharmacists.
James G Stevenson, Robert Popovian, Ira Jacobs, Susan Hurst, Lesley G Shane

Ann Pharmacother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
George Dranitsaris, Lesley G Shane, Jean-Philippe Galanaud, Gunar Stemer, Philippe Debourdeau

Support Care Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.
George Dranitsaris, Lesley G Shane, Mark Crowther, Guillaume Feugere, Seth Woodruff

Clinicoecon Outcomes Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.
Ira Jacobs, Danielle Petersel, Lesley G Shane, Chee-Keng Ng, Carol Kirchhoff

BioDrugs· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
George Dranitsaris, Lesley Shane, Laura Burgers, Seth Woodruff

Clin Appl Thromb Hemost· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient attitudes and understanding about biosimilars: an international cross-sectional survey.
Ira Jacobs, Ena Singh, K Lea Sewell, Ahmad Al-Sabbagh, Lesley G Shane

Patient Prefer Adherence· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis